Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market size is set to grow by USD 2.24 billion from 2024-2028, Growing geriatric population boost the market, Technavio

NEW YORK, June 27, 2024 /PRNewswire/ — The global diffuse large B-cell lymphoma (DLBCL) therapeutics market size is estimated to grow by USD 2.24 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 8.09% during the forecast period. Growing geriatric population is driving market growth, with a trend towards technological advances. However, cytotoxicity of drugs and inclination toward radiation treatments poses a challenge. Key market players include AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., CTI BioPharma Corp., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Market Driver

The DLBCL therapeutics market is witnessing significant advancements with companies investing in new technologies and innovative therapies. Notable developments include chimeric antigen receptor (CAR) T-cell therapy and gene therapy. Novartis and Gilead are key industry players focusing on CAR T-cell therapy, with Yescarta and Kymriah being notable examples. These therapies offer more effective treatments, reduce efforts, and align with individual patient needs. Gene therapy is another promising area, with industry-focused and diversified players making strides. Overall, these technological advances are enhancing treatment efficacy and shaping the DLBCL therapeutics market. 

The Diffuse Large B-Cell Lymphoma (DLBCL) therapeutics market is currently experiencing significant growth due to the increasing number of diagnosed cases and the development of new treatment options. Chemotherapy, such as Rituximab, CHOP, and DLCBL, remains a common treatment method. However, new technologies like CAR-T cell therapy from companies like Novartis and Gilead Sciences are gaining popularity. These innovative treatments offer longer remission periods and improved patient outcomes. Additionally, monoclonal antibodies like Ibrutinib and Idelalisib are making a mark in the market with their ability to target specific proteins in DLBCL cells. The market is expected to continue growing as research and development efforts focus on enhancing treatment efficacy and reducing side effects. 

Research report provides comprehensive data on impact of trend. For more details- Download a Sample Report

Market Challenges

The DLBCL therapeutics market experiences moderate growth due to the use of cytotoxic drugs like vincristine, doxorubicin, and carboplatin, which have adverse side effects and impact normal cells. Radiation therapy, another treatment option, also presents side effects. However, research and development efforts aim to reduce these side effects and create innovative drugs, fostering market growth.The Diffuse Large B-Cell Lymphoma (DLBCL) therapeutics market faces several challenges in providing effective treatments. Chemotherapy, such as Rituximab, is a common treatment, but drug resistance is a significant issue. Inhibitors like Bruton’s Tyrosine Kinase (BTK) and Syk are being explored to address this challenge. However, the high cost of these advanced therapies is a major concern for patients and healthcare systems. Additionally, the need for long-term treatment and potential side effects can impact patient compliance. The market requires innovative solutions to improve treatment efficacy, reduce costs, and enhance patient experience.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This diffuse large b-cell lymphoma (dlbcl) therapeutics market report extensively covers market segmentation by  

Application 1.1 Hospital pharmacy1.2 Retail pharmacy1.3 Online pharmacy1.4 OthersProduct 2.1 Small molecules2.2 BiologicsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Hospital pharmacy- Hospital pharmacies are essential in DLBCL treatment, managing storage, preparation, and dispensing of DLBCL therapeutics. Pharmacists oversee patient care, monitoring adverse effects and drug interactions. Education on medication use and collaboration with healthcare providers ensure optimal care. The hospital pharmacy segment significantly contributes to the DLBCL therapeutics market’s growth due to the hospital-based administration of these treatments. Ensuring safe and effective use of DLBCL therapeutics is the primary role of hospital pharmacies and pharmacists.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

The Diffuse Large B-Cell Lymphoma (DLBCL) therapeutics market encompasses a range of innovative treatments for this type of hematologic malignancy. Key therapeutic classes include monoclonal antibodies, such as Rituximab, and kinase inhibitors, like Ibrutinib. These targeted therapies have revolutionized the treatment landscape for DLBCL, providing effective options for patients with marginal zone lymphoma, Mantle cell lymphoma, Small lymphocytic lymphoma, Chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. Immunomodulatory drugs, such as Liso-cel, also play a significant role in DLBCL treatment. Advanced therapies, like GOLCA and CAR-T cell therapies, are under investigation and hold promise for future developments. Treatment regimens, such as R-CHOP, are commonly used in combination with these targeted therapies to improve patient outcomes. Newer therapies, like Zilovertamab vedotin, are also being explored to address the unmet needs in DLBCL treatment. These therapies target specific proteins, such as BTK and SYK, to inhibit the growth and proliferation of malignant B-cells in lymph nodes and other affected sites, including the thymus.

Market Research Overview

The Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market encompasses innovative treatments and therapies designed to address this type of cancer. Drugs and treatments under development aim to target specific cellular markers and pathways, such as CD20, BCL-2, and CHOP. Monoclonal antibodies, chemotherapies, and immunomodulatory agents are among the therapeutic categories being explored. Nucleic acids, enzymes, and targeted therapies are also being investigated. The market is driven by the increasing incidence of DLBCL and the need for more effective and less toxic treatment options. The goal is to improve patient outcomes and survival rates through the development of new and improved therapies. The market is expected to grow significantly due to the increasing demand for advanced treatments and the ongoing research and development efforts in this field.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationHospital PharmacyRetail PharmacyOnline PharmacyOthersProductSmall MoleculesBiologicsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/diffuse-large-b-cell-lymphoma-dlbcl-therapeutics-market-size-is-set-to-grow-by-usd-2-24-billion-from-2024-2028–growing-geriatric-population-boost-the-market-technavio-302183523.html

SOURCE Technavio